HER1-HER4 expression and co-expression in advanced urothelial carcinoma.
BACKGROUND: The human epidermal growth factor receptor (HER) family is under evaluation as a therapeutic target in urothelial cancer (UC); the significance of expression patterns beyond those of HER2 is unclear. HER1 positivity correlated with better chemotherapy responses (P = 0.02) and HER3/HER4 positivity with poorer responses (P = 0.02 and P = 0.03, respectively).
BACKGROUND: The human epidermal growth factor receptor (HER) family is under evaluation as a therapeutic target in urothelial cancer (UC); the significance of expression patterns beyond those of HER2 is unclear. HER1 positivity correlated with better chemotherapy responses (P = 0.02) and HER3/HER4 positivity with poorer responses (P = 0.02 and P = 0.03, respectively).
What the study was
- Study design
- Randomized Controlled Trial
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- ESMO Open
Why it surfaced
Randomized controlled trial; Topic: Precision oncology and genomic medicine; Score 6/10 → STANDARD priority
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.